These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38905044)
21. Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. Schindler SE; Jasielec MS; Weng H; Hassenstab JJ; Grober E; McCue LM; Morris JC; Holtzman DM; Xiong C; Fagan AM Neurobiol Aging; 2017 Aug; 56():25-32. PubMed ID: 28482211 [TBL] [Abstract][Full Text] [Related]
22. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease. Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478 [TBL] [Abstract][Full Text] [Related]
23. Alteration of regional homogeneity and white matter hyperintensities in amnestic mild cognitive impairment subtypes are related to cognition and CSF biomarkers. Luo X; Jiaerken Y; Huang P; Xu XJ; Qiu T; Jia Y; Shen Z; Guan X; Zhou J; Zhang M; Brain Imaging Behav; 2018 Feb; 12(1):188-200. PubMed ID: 28236166 [TBL] [Abstract][Full Text] [Related]
24. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522 [TBL] [Abstract][Full Text] [Related]
25. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
26. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid. Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990 [TBL] [Abstract][Full Text] [Related]
27. Enhancing the Sensitivity of Memory Tests: Reference Data for the Free and Cued Selective Reminding Test and the Logical Memory Task from Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Brugulat-Serrat A; Cañas-Martínez A; Canals-Gispert L; Marne P; Gramunt N; Milà-Alomà M; Suárez-Calvet M; Arenaza-Urquijo EM; Grau-Rivera O; González-de-Echávarri JM; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL; Sánchez-Benavides G; J Alzheimers Dis; 2021; 84(1):119-128. PubMed ID: 34569957 [TBL] [Abstract][Full Text] [Related]
28. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913 [TBL] [Abstract][Full Text] [Related]
29. Selective Reminding and Free and Cued Selective Reminding in Mild Cognitive Impairment and Alzheimer Disease. Lemos R; Afonso A; Martins C; Waters JH; Blanco FS; Simões MR; Santana I Appl Neuropsychol Adult; 2016; 23(2):85-93. PubMed ID: 26375308 [TBL] [Abstract][Full Text] [Related]
30. Forget About Memory: Disentangling the Amnestic Syndrome in Idiopathic Normal Pressure Hydrocephalus. Lingenberg A; Herrmann FR; Armand S; Péron J; Assal F; Allali G J Alzheimers Dis; 2024; 101(4):1205-1216. PubMed ID: 39302366 [TBL] [Abstract][Full Text] [Related]
31. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
32. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
33. A biomarker study in long-lasting amnestic mild cognitive impairment. Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292 [TBL] [Abstract][Full Text] [Related]
35. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients. Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344 [TBL] [Abstract][Full Text] [Related]
36. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment. He B; Wang L; Xu B; Zhang Y; Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602 [TBL] [Abstract][Full Text] [Related]
37. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment. Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207 [TBL] [Abstract][Full Text] [Related]
38. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD. Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632 [TBL] [Abstract][Full Text] [Related]
39. Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. Trelle AN; Carr VA; Wilson EN; Swarovski MS; Hunt MP; Toueg TN; Tran TT; Channappa D; Corso NK; Thieu MK; Jayakumar M; Nadiadwala A; Guo W; Tanner NJ; Bernstein JD; Litovsky CP; Guerin SA; Khazenzon AM; Harrison MB; Rutt BK; Deutsch GK; Chin FT; Davidzon GA; Hall JN; Sha SJ; Fredericks CA; Andreasson KI; Kerchner GA; Wagner AD; Mormino EC Neurology; 2021 Mar; 96(10):e1470-e1481. PubMed ID: 33408146 [TBL] [Abstract][Full Text] [Related]
40. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer's disease pathology. Silva-Spínola A; Leitão MJ; Nadal A; Le Bastard N; Santana I; Baldeiras I Alzheimers Res Ther; 2024 Mar; 16(1):51. PubMed ID: 38454502 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]